2687222-58-6
Chemical Structure
Vizenpistat
Synonym(s): SR-8541A
- CAS. Nr.: 2687222-58-6
- Formula:C15H21N5O4S
- Molecular Weight:367.42
IUPAC Name: 4-(6,7-dimethoxyquinazolin-4-yl)-1,4-diazepane-1-sulfonamide
InChIKey: KZXIIZCLNZSOEZ-UHFFFAOYSA-N
SMILES: O=S(N)(N1CCN(CCC1)C2=C3C=C(OC)C(OC)=CC3=NC=N2)=O
Biological Activity: Vizenpistat (SR-8541A) is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vizenpistat | 99.14% | Vizenpistat (SR-8541A) is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kaadige M.R., et al. Abstract CT200: Phase I dose-escalation study of ENPP1 inhibitor, vizenpistat, for the treatment of solid tumors. Cancer Research, 2026, 86(8_Supplement): CT200.
- [2]. Larsen A.S., et al. Abstract CT221: A progress report for a Phase 1b/2 study of ENPP1 inhibitor, vizenpistat in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer. Cancer Research, 2026, 86(8_Supplement): CT221.
